FDA
-
-
-
-
-
-
-
AN2 Therapeutics receives FDA clearance for M. abscessus lung disease trial
-
-
-
-
-
-
-
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
-
-
-
-
-
-
-
AN2 Therapeutics Reports Data from the Phase 3 Portion of Previously Terminated EBO-301 Study and Outlines Future Milestones from Boron Chemistry Pipeline
-
-
-
-
-
-
-
JMP Securities Reiterates Market Outperform Rating on AN2 Therapeutics (ANTX)
-
-
-
-
-
-
-
JMP Securities Upgrades AN2 Therapeutics (ANTX) to Market Outperform
-
-
-
-
-
-
-
AN2 Therapeutics Reports Second Quarter 2023 Financial Results and Recent Highlights
-
-
-
-
-
-
-
AN2 Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates
-
323,729 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

